Common Contracts
4 similar Asset Purchase Agreement contracts by Exagen Diagnostics Inc, Exagen Inc.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • August 23rd, 2019 • Exagen Inc. • Services-medical laboratories • California
THIS ASSET PURCHASE AGREEMENT (“Agreement”) is made and entered into as of February 9, 2009, by and among: CYPRESS BIOSCIENCE, INC., a Delaware corporation (“Cypress”); and CELLATOPE CORPORATION, a Delaware corporation (“Cellatope”). Each of Cypress and Cellatope is sometimes referred to herein as a “party” and together Cypress and Cellatope are sometimes referred to herein as the “parties.” Certain other capitalized terms used in this Agreement are defined in Exhibit A.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • February 1st, 2019 • Exagen Inc. • Services-medical laboratories • California
THIS ASSET PURCHASE AGREEMENT (“Agreement”) is made and entered into as of February 9, 2009, by and among: CYPRESS BIOSCIENCE, INC., a Delaware corporation (“Cypress”); and CELLATOPE CORPORATION, a Delaware corporation (“Cellatope”). Each of Cypress and Cellatope is sometimes referred to herein as a “party” and together Cypress and Cellatope are sometimes referred to herein as the “parties.” Certain other capitalized terms used in this Agreement are defined in Exhibit A.
ASSET PURCHASE AGREEMENT between: CYPRESS BIOSCIENCE, INC., a Delaware corporation and CELLATOPE CORPORATION, a Delaware corporation Dated as of February 9, 2009Asset Purchase Agreement • September 19th, 2014 • Exagen Diagnostics Inc • Services-medical laboratories • California
THIS ASSET PURCHASE AGREEMENT (“Agreement”) is made and entered into as of February 9, 2009, by and among: CYPRESS BIOSCIENCE, INC., a Delaware corporation (“Cypress”); and CELLATOPE CORPORATION, a Delaware corporation (“Cellatope”). Each of Cypress and Cellatope is sometimes referred to herein as a “party” and together Cypress and Cellatope are sometimes referred to herein as the “parties.” Certain other capitalized terms used in this Agreement are defined in Exhibit A.
ASSET PURCHASE AGREEMENT between: CYPRESS BIOSCIENCE, INC., a Delaware corporation and CELLATOPE CORPORATION, a Delaware corporation Dated as of February 9, 2009Asset Purchase Agreement • August 4th, 2014 • Exagen Diagnostics Inc • Services-medical laboratories • California
THIS ASSET PURCHASE AGREEMENT (“Agreement”) is made and entered into as of February 9, 2009, by and among: CYPRESS BIOSCIENCE, INC., a Delaware corporation (“Cypress”); and CELLATOPE CORPORATION, a Delaware corporation (“Cellatope”). Each of Cypress and Cellatope is sometimes referred to herein as a “party” and together Cypress and Cellatope are sometimes referred to herein as the “parties.” Certain other capitalized terms used in this Agreement are defined in Exhibit A.
